#ChallengeAccepted: 2 weeks, 10,000+ steps for 12 of the 14 days = 120,000+ steps #TeamCastle really stepped up this month for the firm-wide #SpringIntoAction Wellness Challenge. Together, 79 team members walked 12,357,321 steps (with 9 of them exceeding 200,000 steps), and the top stepper reached 388,163 steps. Congratulations to our fearless fitness warriors! #CastleCulture #WeLoveOurPeople??
Castle Biosciences, Inc.
生物技术研究
Friendswood，Texas 13,924 位关注者
Improving health through innovative tests that guide patient care
关于我们
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx?-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx?-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath? Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher? Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx?-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- 网站
-
https://castlebiosciences.com/
Castle Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Friendswood，Texas
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Diagnostic Cancer Testing、Uveal Melanoma、Cutaneous Melanoma、Melanoma、Skin Cancer、Next Gen Sequencing、Cutaneous Squamous Cell Carcinoma、Gene Expression Profile Tests、Barrett's Esophagus、Esophageal Adenocarcinoma和Dermatologic Cancer
地点
Castle Biosciences, Inc.员工
-
Francesca Rancati
Scientific Leadership | Medical Education | Cross-Functional Collaboration | Team management | Strategic Planning | Clinical Research | Stakeholder…
-
Matthew Turner
-
Kathleen Irwin
Corporate Communications Manager at Castle Biosciences, Inc.
-
Vicki Fish
Experienced biotech executive with proven success- commercialization, sales management, leading high performance teams.
动态
-
We are heading to Tampa for the #SSO2025 Annual Meeting! Make sure to stop by our booth (#212) tomorrow through Saturday. DecisionDx-Melanoma | DecisionDx-SCC | MyPath Melanoma
-
-
Clinical decision-making in melanoma care goes beyond traditional staging. DecisionDx-Melanoma provides personalized tumor biology insights to help identify patients at higher risk for recurrence or metastasis—leading to more tailored management strategies. Explore real-world case studies demonstrating how this test supports risk-aligned care plans and helps guide surveillance and treatment decisions. ?? Learn more about Cases with Castle—click the link to explore: https://hubs.la/Q03chLbt0 Castle Biosciences, Inc.
-
-
Thank you, Leah, for sharing your story and your melanoma journey with us. DecisionDx-Melanoma
Being the first patient ambassador to speak in person at a national sales meeting for Castle Biosciences, Inc. DecisionDx Melanoma test in Las Vegas was an incredible honor. Sharing my melanoma journey with the team behind this groundbreaking test was both humbling and empowering. As a melanoma survivor, I know firsthand the uncertainty and fear that come with a cancer diagnosis. The DecisionDx-Melanoma test played a crucial role in helping me move forward after cancer by providing valuable insights into my risk of recurrence, allowing my doctors and me to make more informed decisions about my long-term care. Standing in front of the Castle Biosciences team, I had the opportunity to show them the real-life impact of their work—how their dedication to advancing melanoma diagnostics has given patients like me clarity, confidence, and a path forward. It was so meaningful to express my gratitude and to emphasize how much their innovation means to those facing melanoma. My story is just one of many, but it’s a testament to the power of personalized medicine in transforming patient care. Being able to connect with the people who develop and deliver this test reinforced the importance of their mission, and I hope my words inspired them as much as their work has inspired me. I look forward to continuing to partner with this incredible company in so many ways in the future. This is only the beginning ????? #melanoma #melanomasurvivor #castlebiosciences #decisiondx #decisiondxmelanoma #melanomapatient #melanomawarrior #melanomaawareness #melanomaskincancer #skincancer #skincancerawareness #cancer #cancerprevention #cancersurvivor
-
-
-
-
-
+2
-
-
#TeamCastle hit the pavement this past weekend in support of AAD’s “Skin Cancer, Take a Hike!” event, helping them raise funds to promote skin cancer awareness and prevention. We are so proud of our team for earning a spot on the leaderboard — "Top Team" raising $2,500 and "Most Members" with 25 participants. American Academy of Dermatology #AAD2025 #CastleCares #CastleCulture
-
-
Residents – Join us at AAD in our booth #1661 for early-access to our booth happy hour starting at 2:15 PM! Everyone else stop by at 3 PM for drinks, discussion, and Whac-A-Mole with your esteemed colleagues! DecisionDx-Melanoma | DecisionDx-SCC | MyPath Melanoma
-
-
Join us bright and early at #AAD2024 for a 2-mile walk as we increase awareness and protect lives against skin cancer! DecisionDx-Melanoma | DecisionDx-SCC | MyPath Melanoma American Academy of Dermatology
-
-
NEXT WEEK: Castle's GI Medical Director, Emmanuel Gorospe, will present at the Precision Medicine TRI-CON Conference. He will discuss how advances in spatial biology are expanding our knowledge of diseases, enabling us to look deeper into tissue structures to identify molecular changes before they are diagnosed by standard histopathology. His talk will explore the development and use of TissueCypher, a spatialomics-based test that is guiding management of patients with Barrett’s esophagus by predicting the risk of progression to esophageal cancer. These advances are making personalized medicine possible and hold the promise of improving patient care.
-
-
We are almost one week in... #TeamCastle is stepping it up this month for the firm-wide #SpringIntoAction Wellness Challenge, happening 3/1-15. The challenge: 10,000+ steps for 12 of the 14 days. The reward: feeling fantastic, improving our health, and getting fancy with some #CastleSwag! #CastleCulture #WeLoveOurPeople??
-
-
Join us this afternoon to hear from Emily Ruiz, MD, MPH, FAAD about how DecisionDx-SCC risk stratifies high-risk SCC patients in a novel and independent cohort. American Academy of Dermatology
-